I 039
Alternative Names: I-039Latest Information Update: 24 Aug 2023
At a glance
- Originator Shanghai Pharmaceuticals Holding
- Class Anti-inflammatories
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammatory bowel diseases
Most Recent Events
- 24 Aug 2023 Preclinical trials in Inflammatory bowel diseases in China (unspecified route), prior to August 2023 (Shanghai Pharmaceutical Group pipeline, August 2023)
- 28 Jul 2023 I 039 obtains the clinical trial approval notice for Inflammatory bowel disease (Shanghai Pharmaceutical Group pipeline, August 2023)
- 28 Jul 2023 Pharmacodynamics data from preclinical trials in Inflammatory bowel disease released by Shanghai Pharmaceutical Group (Shanghai Pharmaceutical Group pipeline, August 2023)